Sun Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sun Lee has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Daisy Liu
Analysis Group, Inc., Boston, USA
2 shared publicationsDonna Rowen
Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK
2 shared publications- Elamin H. Elbasha
Health Economic and Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA
2 shared publications - Hela Romdhani
Analysis Group, Inc., Boston, USA
2 shared publications - Jipan Xie
XL Source, Inc., Los Angeles, USA
2 shared publications - Matthew. S. Kelly
University of Arkansas for Medical Sciences
2 shared publications
Latest Publications
- Open Access
- 10 December 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 5-33
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews
Background Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluate the economic value of pneumococcal vaccines. Objectives This study aimed to synthesize utility values used in CUAs of pneumococcal vaccines in adult populations in North America and Europe and to summarize global utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in adults. Methods Two targeted literature reviews were conducted in June 2024 using MEDLINE to identify CUAs of pneumococcal vaccines and original studies on health utilities for pneumococcal disease and PMS in adults. References from existing literature reviews on QoL associated with pneumococcal disease and CUAs of pneumococcal vaccines were also screened to identify additional original utility studies. Health utility input values applied in the CUAs were summarized, and the original source studies were reviewed. Utility and disutility inputs were converted to QALY decrements using disease durations reported in the CUAs. Methods and utility estimates from original utility studies were summarized for each health state. Results Sixty-five CUAs focusing on adults in North America and Europe were identified. These CUAs frequently reported utility values and QALY decrements. The ranges of reported and derived QALY decrements were 0.006–0.8 for unspecified invasive pneumococcal disease (IPD), 0.0013–0.1759 for meningitis, 0.0010–0.1759 for non-meningitis IPD, 0.0002–0.13 for inpatient pneumonia, and 0.0001–0.0115 for outpatient pneumonia. The ranges of reported utility values for PMS were 0.319–0.83 for neurological deficits and 0.635–0.91 for hearing loss. Twenty-five original utility studies in adults were identified, published between 1993 and 2022. Utility estimates from these studies showed considerable variability, with ranges of − 0.330 to 0.39 for meningitis, − 0.331 to 0.93 for non-meningitis IPD, − 0.054 to 0.71 for inpatient pneumonia, 0.35–0.825 for outpatient pneumonia, 0.217–0.89 for neurological deficits, and 0.433–0.89 for hearing loss. This variability was primarily attributable to differences in case definitions, preference weights, and geographical locations. Conclusions This review identified substantial QoL burden associated with pneumococcal disease and PMS in adults; however, considerable variability in utility estimates exists. Utility inputs in CUAs of pneumococcal vaccines in adults often rely upon assumptions, pediatric studies, or utilities from other diseases, and there is relatively little data on the health utilities of IPD and neurological deficits in adults. Given the importance of health utilities in economic evaluations, CUAs should carefully select utility values by considering methodological robustness, the representativeness of health states, and the time frame over which health utilities are assessed and evaluate alternative sources and assumptions in sensitivity analyses.
- 10 December 2025
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 10 (1) , 5-33
Open AccessGlobal Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews
Background Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluate the economic value of pneumococcal vaccines. Objectives This study aimed to synthesize utility values used in CUAs of pneumococcal vaccines in adult populations in North America and Europe and to summarize global utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in adults. Methods Two targeted literature reviews were conducted in June 2024 using MEDLINE to identify CUAs of pneumococcal vaccines and original studies on health utilities for pneumococcal disease and PMS in adults. References from existing literature reviews on QoL associated with pneumococcal disease and CUAs of pneumococcal vaccines were also screened to identify additional original utility studies. Health utility input values applied in the CUAs were summarized, and the original source studies were reviewed. Utility and disutility inputs were converted to QALY decrements using disease durations reported in the CUAs. Methods and utility estimates from original utility studies were summarized for each health state. Results Sixty-five CUAs focusing on adults in North America and Europe were identified. These CUAs frequently reported utility values and QALY decrements. The ranges of reported and derived QALY decrements were 0.006–0.8 for unspecified invasive pneumococcal disease (IPD), 0.0013–0.1759 for meningitis, 0.0010–0.1759 for non-meningitis IPD, 0.0002–0.13 for inpatient pneumonia, and 0.0001–0.0115 for outpatient pneumonia. The ranges of reported utility values for PMS were 0.319–0.83 for neurological deficits and 0.635–0.91 for hearing loss. Twenty-five original utility studies in adults were identified, published between 1993 and 2022. Utility estimates from these studies showed considerable variability, with ranges of − 0.330 to 0.39 for meningitis, − 0.331 to 0.93 for non-meningitis IPD, − 0.054 to 0.71 for inpatient pneumonia, 0.35–0.825 for outpatient pneumonia, 0.217–0.89 for neurological deficits, and 0.433–0.89 for hearing loss. This variability was primarily attributable to differences in case definitions, preference weights, and geographical locations. Conclusions This review identified substantial QoL burden associated with pneumococcal disease and PMS in adults; however, considerable variability in utility estimates exists. Utility inputs in CUAs of pneumococcal vaccines in adults often rely upon assumptions, pediatric studies, or utilities from other diseases, and there is relatively little data on the health utilities of IPD and neurological deficits in adults. Given the importance of health utilities in economic evaluations, CUAs should carefully select utility values by considering methodological robustness, the representativeness of health states, and the time frame over which health utilities are assessed and evaluate alternative sources and assumptions in sensitivity analyses.
- 23 May 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (9) , 1001-1045
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
Background Pneumococcal disease can significantly impact the quality of life (QoL) of children. Health utilities are used to measure the disease burden and calculate quality-adjusted life year (QALY) estimates. These estimates provide critical inputs in economic evaluations of pneumococcal vaccines in children. Objectives This study aimed to synthesize utility values used in cost-utility analyses (CUAs) of pediatric pneumococcal vaccines and to summarize published utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in children on a global scale. Methods Two targeted literature reviews were conducted to identify CUAs of pediatric pneumococcal vaccines and original studies on health utilities of pneumococcal disease and PMS. Both literature reviews identified relevant studies using published reviews, supplemented by de novo searches conducted in MEDLINE in June 2024 to cover periods not included in those reviews. References from published literature reviews on QoL of pneumococcal disease and CUAs were screened to identify additional original utility studies. Health utility values applied in the CUAs were summarized and the source studies for these utilities were reviewed. For original utility studies, methods and utility estimates were summarized for each condition. Results The study identified 45 CUAs of pediatric pneumococcal vaccines in North America and Europe published from 2004 to 2024, and 21 original utility studies on pneumococcal disease or PMS in children published globally from 1994 to 2017. QALY decrement was the most common utility input in CUAs. Most CUAs referenced an earlier CUA for utility inputs, which were often sourced from one or two original utility studies for each health state. Most source studies were published more than two decades ago; some common source studies were conducted in adults. Utility estimates from original studies showed considerable variability, with ranges of −0.330 to 0.6882 for meningitis, −0.331 to 0.93 for non-meningitis invasive pneumococcal disease (IPD), −0.054 to 0.71 for inpatient pneumonia, 0.412–0.82 for outpatient pneumonia, 0.389–0.97 for acute otitis media (AOM)/simple AOM, 0.434–0.540 for recurrent AOM, −0.33 to 0.89 for neurological deficits, and 0.217–0.97 for hearing loss. Variability in methods, including in the surveyed population, utility elicitation method, and use of different country-specific preference weights, substantially impacted utility values. Overall, the methods were not suitable for temporary health states. Additionally, many studies used instruments that have not been validated in children. Conclusions Original utility studies demonstrated that pneumococcal disease and PMS are associated with impaired QoL in children; however, there was considerable variability in utility estimates across studies, reflecting the inherent methodological challenges in estimating utilities for acute diseases in children. Most CUAs referenced previous CUAs for health utility values, which were sourced from a limited number of outdated original utility studies. Contemporary data and methods adapted for acute diseases in children are needed for future studies. Given the significance of health utilities in the economic valuations of new pneumococcal vaccines, utility values should be carefully selected in CUAs, considering alternative sources and assumptions.
- 23 May 2025
- Published by Springer Nature in PharmacoEconomics
- Vol. 43 (9) , 1001-1045
Global Assessment of Health Utilities Associated with Pneumococcal Disease in Children—Targeted Literature Reviews
Background Pneumococcal disease can significantly impact the quality of life (QoL) of children. Health utilities are used to measure the disease burden and calculate quality-adjusted life year (QALY) estimates. These estimates provide critical inputs in economic evaluations of pneumococcal vaccines in children. Objectives This study aimed to synthesize utility values used in cost-utility analyses (CUAs) of pediatric pneumococcal vaccines and to summarize published utility studies on pneumococcal disease and post-meningitis sequelae (PMS) in children on a global scale. Methods Two targeted literature reviews were conducted to identify CUAs of pediatric pneumococcal vaccines and original studies on health utilities of pneumococcal disease and PMS. Both literature reviews identified relevant studies using published reviews, supplemented by de novo searches conducted in MEDLINE in June 2024 to cover periods not included in those reviews. References from published literature reviews on QoL of pneumococcal disease and CUAs were screened to identify additional original utility studies. Health utility values applied in the CUAs were summarized and the source studies for these utilities were reviewed. For original utility studies, methods and utility estimates were summarized for each condition. Results The study identified 45 CUAs of pediatric pneumococcal vaccines in North America and Europe published from 2004 to 2024, and 21 original utility studies on pneumococcal disease or PMS in children published globally from 1994 to 2017. QALY decrement was the most common utility input in CUAs. Most CUAs referenced an earlier CUA for utility inputs, which were often sourced from one or two original utility studies for each health state. Most source studies were published more than two decades ago; some common source studies were conducted in adults. Utility estimates from original studies showed considerable variability, with ranges of −0.330 to 0.6882 for meningitis, −0.331 to 0.93 for non-meningitis invasive pneumococcal disease (IPD), −0.054 to 0.71 for inpatient pneumonia, 0.412–0.82 for outpatient pneumonia, 0.389–0.97 for acute otitis media (AOM)/simple AOM, 0.434–0.540 for recurrent AOM, −0.33 to 0.89 for neurological deficits, and 0.217–0.97 for hearing loss. Variability in methods, including in the surveyed population, utility elicitation method, and use of different country-specific preference weights, substantially impacted utility values. Overall, the methods were not suitable for temporary health states. Additionally, many studies used instruments that have not been validated in children. Conclusions Original utility studies demonstrated that pneumococcal disease and PMS are associated with impaired QoL in children; however, there was considerable variability in utility estimates across studies, reflecting the inherent methodological challenges in estimating utilities for acute diseases in children. Most CUAs referenced previous CUAs for health utility values, which were sourced from a limited number of outdated original utility studies. Contemporary data and methods adapted for acute diseases in children are needed for future studies. Given the significance of health utilities in the economic valuations of new pneumococcal vaccines, utility values should be carefully selected in CUAs, considering alternative sources and assumptions.
- 1 March 2021
- Published by Elsevier in Patient Education and Counseling
- Vol. 104 (3) , 649-653
Assessing communication skills in student pharmacists—Psychometric validation of Global Communication Rubric
- 1 March 2021
- Published by Elsevier in Patient Education and Counseling
- Vol. 104 (3) , 649-653
Assessing communication skills in student pharmacists—Psychometric validation of Global Communication Rubric
- Open Access
Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma
BACKGROUND: The objective of the current study was to determine the accuracy of magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) for detecting lymph node metastases in patients with uterine cervical carcinoma compared with thin‐section histopathologic results from systemic lymphadenectomy.METHODS: Twenty‐two patients with International Federation of Obstetrics and Gynecology (FIGO) Stage IB–IVA cervical carcinoma who underwent both MRI and PET/CT before lymphadenectomy were included in this study. Lymphadenectomy involved removing all visible lymph nodes in the surgical fields. To enable region‐specific comparisons, paraaortic and pelvic lymph nodes were divided into seven regions: the paraaortic area, both common iliac areas, both external iliac areas, and both internal iliac/obturator areas. Histopathologic evaluation of lymph nodes was the diagnostic standard. Chi‐square analysis was used to compare the accuracy of MRI and PET/CT for the detection of metastatic lymph nodes. A P value ≤ 0.05 was considered statistically significant.RESULTS: With MRI, the sensitivity, specificity, and accuracy rates for detecting metastatic lymph nodes in each lymph node group were 30.3% (10 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 72.7% (122 of 154 lymph node groups), respectively; with PET/CT, those rates were 57.6% (19 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 85.1% (131 of 154 lymph node groups), respectively. Statistical analysis showed that PET/CT was more sensitive than MRI (P = 0.026) but that there were no statistical differences noted with regard to specificity (P = 1.000) or accuracy (P = 0.180). Power analysis demonstrated that a sample size of 685 lymph node groups (98 patients) would be necessary to demonstrate that PET/CT was more accurate than MRI (α = 0.05; β = 0.80).CONCLUSIONS: PET/CT was more sensitive than MRI for detecting lymph node metastases in patients with uterine cervical carcinoma. Cancer 2006. © 2006 American Cancer Society.
Open AccessComparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma
BACKGROUND: The objective of the current study was to determine the accuracy of magnetic resonance imaging (MRI) and positron emission tomography/computed tomography (PET/CT) for detecting lymph node metastases in patients with uterine cervical carcinoma compared with thin‐section histopathologic results from systemic lymphadenectomy.METHODS: Twenty‐two patients with International Federation of Obstetrics and Gynecology (FIGO) Stage IB–IVA cervical carcinoma who underwent both MRI and PET/CT before lymphadenectomy were included in this study. Lymphadenectomy involved removing all visible lymph nodes in the surgical fields. To enable region‐specific comparisons, paraaortic and pelvic lymph nodes were divided into seven regions: the paraaortic area, both common iliac areas, both external iliac areas, and both internal iliac/obturator areas. Histopathologic evaluation of lymph nodes was the diagnostic standard. Chi‐square analysis was used to compare the accuracy of MRI and PET/CT for the detection of metastatic lymph nodes. A P value ≤ 0.05 was considered statistically significant.RESULTS: With MRI, the sensitivity, specificity, and accuracy rates for detecting metastatic lymph nodes in each lymph node group were 30.3% (10 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 72.7% (122 of 154 lymph node groups), respectively; with PET/CT, those rates were 57.6% (19 of 33 lymph node groups), 92.6% (112 of 121 lymph node groups), and 85.1% (131 of 154 lymph node groups), respectively. Statistical analysis showed that PET/CT was more sensitive than MRI (P = 0.026) but that there were no statistical differences noted with regard to specificity (P = 1.000) or accuracy (P = 0.180). Power analysis demonstrated that a sample size of 685 lymph node groups (98 patients) would be necessary to demonstrate that PET/CT was more accurate than MRI (α = 0.05; β = 0.80).CONCLUSIONS: PET/CT was more sensitive than MRI for detecting lymph node metastases in patients with uterine cervical carcinoma. Cancer 2006. © 2006 American Cancer Society.